313 related articles for article (PubMed ID: 31558250)
21. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.
Martin Arias LH; Martin Gonzalez A; Sanz Fadrique R; Salgueiro E; Sainz M
Int J Clin Pharm; 2018 Aug; 40(4):928-935. PubMed ID: 30066292
[TBL] [Abstract][Full Text] [Related]
22. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
23. Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database.
Konstantinov K; Dolladille C; Gillet B; Alexandre J; Aouba A; Deshayes S; Repesse Y
Haemophilia; 2023 Jan; 29(1):186-192. PubMed ID: 36367755
[TBL] [Abstract][Full Text] [Related]
24. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
25. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
27. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
29. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wei Q; Wu X
Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
[No Abstract] [Full Text] [Related]
30. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
31. Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021.
Liu X; Xu Z; Ma J; Zhang A; Li Z; Qi G; Li Z; Wei F; Zhong L
J Infect Chemother; 2023 Feb; 29(2):136-142. PubMed ID: 36270450
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
[TBL] [Abstract][Full Text] [Related]
33. A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Song TJ
Mult Scler; 2022 Nov; 28(13):2112-2123. PubMed ID: 35822296
[TBL] [Abstract][Full Text] [Related]
34. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
35. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
36. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC.
Waliany S; Zhu H; Wakelee H; Padda SK; Das M; Ramchandran K; Myall NJ; Chen T; Witteles RM; Neal JW
J Thorac Oncol; 2021 Dec; 16(12):2029-2039. PubMed ID: 34418561
[TBL] [Abstract][Full Text] [Related]
37. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M; Lebrun-Vignes B; Pariente A; Shaffer CM; Malouf GG; Dureau P; Potey C; Funck-Brentano C; Roden DM; Moslehi JJ; Salem JE
Arch Cardiovasc Dis; 2020 Jan; 113(1):9-21. PubMed ID: 31685432
[TBL] [Abstract][Full Text] [Related]
38. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
39. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
[TBL] [Abstract][Full Text] [Related]
40. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis.
Park T; Hwang M
Expert Rev Cardiovasc Ther; 2024 Jun; 22(6):273-283. PubMed ID: 38722712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
